Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference

   Kuros Biosciences AG / Key word(s): Conference
   Kuros Biosciences to Present at the CG 2024 Musculoskeletal
   Conference
   01.02.2024 / 07:00 CET/CEST
     ____________________________________________________________

   
   Schlieren (Zurich), Switzerland, February 1, 2024 - Kuros
   Biosciences ("Kuros" or "the Company"), a leader in next
   generation bone graft technologies, today announced it will
   present at the CG 2024 Musculoskeletal Conference, to be held in
   San Francisco on February 12, 2024. At the conference, management
   will discuss its novel MagnetOs portfolio of products and its
   application to spinal fusion.

Presentation details are as follows:

   Presenter:  Chris Fair, Chief Executive Officer of Kuros
   Biosciences
   Presentation time: 10:00 am - 10:25 am EDT
   Location: Colonial Room

   Additional executive leadership team members in attendance:
   Daniel Geiger, Chief Financial Officer and Joost de Bruijn,
   Executive Director and President of Innovation and Strategy

   A replay of the presentation will be available for 90 days
   following the conference.  You may access the replay directly
   here, or via the Reports & Corporate Governance section of Kuros'
   website within "Reports & Presentations".

   Kuros management will also be available for one on ones during
   the conference.  Please contact your CG representative should you
   have interest in setting up a meeting.

   About the CG Musculoskeletal Conference 2024
   The CG ("Canaccord Genuity") Musculoskeletal Conference is a
   one-day event to explore the current state of orthopedics,
   robotic surgery, imaging/enabling technologies, biologics, and
   regenerative medicine companies.
   About MagnetOs
   MagnetOs is a bone graft like no other: thanks to its
   NeedleGrip^TM surface technology, it grows bone even in soft
   tissues.* This surface technology provides traction for our
   body's vitally important 'pro-healing' immune cells (M2
   macrophages).^1,2 This in turn, unlocks previously untapped
   potential to stimulate stem cells - and form new bone throughout
   the graft.^§3-6  The growing body of science behind NeedleGripTM
   is called osteoimmunology. But for surgeons and their patients it
   means one thing: a more predictable fusion.^¶5,6

   About Kuros Biosciences
   Kuros Biosciences is a fast-growing leader in the development of
   spinal fusion biologics that ease the burden of back pain. With
   locations in the United States, Switzerland and the Netherlands,
   the company is listed on the SIX Swiss Exchange.  The company's
   first commercial product, MagnetOs, is a unique advanced bone
   graft that has already been used successfully across three
   continents and in over 25,000 fusion surgeries.

   Forward Looking Statements
   This media release contains certain forward-looking statements
   that involve risks and uncertainties that could cause actual
   results to be materially different from historical results or
   from any future results expressed or implied by such
   forward-looking statements. You are urged to consider statements
   that include the words "will" or "expect" or the negative of
   those words or other similar words to be uncertain and
   forward-looking. Factors that may cause actual results to differ
   materially from any future results expressed or implied by any
   forward-looking statements include scientific, business, economic
   and financial factors, Against the background of these
   uncertainties, readers should not rely on forward-looking
   statements. The Company assumes no responsibility for updating
   forward-looking statements or adapting them to future events or
   developments.
   1. Duan, et al. eCM. 2019;37:60-73
   2. Van Dijk, et al. eCM. 2021;41:756-73
   3. Van Dijk, et al. JOR Spine. 2018;e1039
   4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater.
   2019;107(6):2080-2090
   5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276-E287
   *In large animal models
   Results from in vivo laboratory testing may not be predictive of
   clinical experience in humans.
   For important safety and intended use information please visit
   kurosbio.com
   MagnetOs is not cleared by the FDA or TGA as an osteoinductive
   bone graft
   §For a 510(k)-cleared synthetic bone graft
   ¶MagnetOs has been proven to generate more predictable fusions
   than two commercially available alternatives in an ovine model of
   posterolateral fusion.

   For further information, please contact:
   Kuros Biosciences AG
   Daniel Geiger
   Chief Financial Officer
   t: +41 44 733 47 47
   e: daniel.geiger@kurosbio.com LifeSci Advisors
   Sandya von der Weid
   Investor Relations
   t: +41 78 680 0538
   e: svonderweid@lifesciadvisors.com

____________________________________________________________

   End of Media Release
     ____________________________________________________________

   Language:    English
   Company:     Kuros Biosciences AG
                Wagistrasse 25
                8952 Schlieren
                Switzerland
   Phone:       +41 44 733 4747
   Fax:         +41 44 733 4740
   E-mail:      info@kurosbio.com
   Internet:    www.kurosbio.com
   ISIN:        CH0325814116
   Valor:       32581411
   Listed:      SIX Swiss Exchange
   EQS News ID: 1827077

   End of News EQS News Service
     ____________________________________________________________

1827077 01.02.2024 CET/CEST